Pharmaceutical compositions comprising synergistic combinations of herbal compounds from Mitragyna speciosa, Piper methysticum, Curcuma longa, Scutellaria baicalensis, Piper nigrum, Cannabis sativa, Camellia sinensis, Sophora japonica, and optionally Valeriana officinalis and 4-amino-3-phenylbutanoic acid are provided for treating pain and reducing opioid use. The compositions comprise defined ratios of the extracts optimized for enhanced analgesic efficacy and opioid-sparing effects. Methods of administering the compositions to subjects in need thereof result in significant reductions in pain and opioid use compared to the individual components. The unique multi-component formulations take advantage of synergistic interactions between extracts with analgesic, anxiolytic, and opioid use disorder mitigating properties.

In a first aspect, the invention pertains to a method for identifying a therapeutic composition against cancer comprising at least one cannabinoid. It is based on a holistic approach that relies on determining its therapeutic efficacy of a composition comprising at least one cannabinoid and by performing a computational analysis on the resulting data. In additional aspects, the invention pertains to therapeutic compositions comprising at least one cannabinoid and their use for the treatment of a condition or disease. Furthermore, the invention pertains to an in-vitro method for the personalization of cannabis-based therapy. Said method relies on providing a patient sample and performing a multiomic analysis on said patient sample. After predicting the patient's response to a therapeutic composition comprising at least one cannabinoid, a therapeutic composition comprising at least one cannabinoid is selected for treatment of the patient.

Provided are pharmaceutical compositions comprising cannabis such that when combusted produces cannabidiolic acid (CBDA) for inhalation. Also provided are pharmaceutical composition for inhalation by a subject comprising tetrahy drocannabinol (THC), tetrahydrocannabinolic acid (THCA), cannabidiol (CBD), cannabidiolic acid (CBDA), and cannabigerol (CBG). Also provided are methods of enhancing cannabidiolic acid (CBDA) in a pharmaceutical composition for inhalation. Methods of use of embodiments of the pharmaceutical composition and kits comprising embodiments of the pharmaceutical composition are provided herein. Unit dosage form medicaments and compositions for vaporization by a subject comprising cannabinoids are also disclosed herein.

A crystalline cannabinoid powder includes cannabinoid crystal particles having a cannabinoid purity of at least 95% by weight and a Specific Surface Area (SSA) of at least 0.7 m2/g. A crystalline cannabinoid powder includes cannabinoid crystal particles having a degree of crystallinity of at least 90% and a Specific Surface Area (SSA) of at least 0.7 m2/g. These powders may be prepared by a dry-milling or wet-milling method, and alternatively by a re-crystallization method.

The present invention provides a pharmaceutical composition including cannabigcrol. and methods of using same, such as for increasing therapeutic efficacy of an immune checkpoint inhibitor, or for the treatment of cancer.

An orally dissolvable or chewable tableted powder formulation is presented. The formulation includes one or more carrier systems including one or more liquid or solid self-emulsifying systems loaded with cannabinoids in an amount of at least 10% by weight of the tableted powder formulation. The one or more self-emulsifying systems includes: at least one or more surfactants, one or more lipids and one or more isolated or synthetic cannabinoids when self-emulsifying system is a liquid self-emulsifying system, and at least one or more surfactants, one or more waxes and one or more isolated or synthetic cannabinoids when self-emulsifying system is a solid self-emulsifying system. The formulation further includes one or more water-soluble agents in an amount of 20-80% by weight of the tableted powder formulation and one or more flavors. The one or more surfactants includes one or more surfactants having a chemical structure that includes a polyethylene glycol moiety.

The invention relates generally to a cryogenic process for making cannabinoid nanoparticles and compositions made thereby.

The invention relates generally to beverage compositions comprising cryogenically produced cannabinoid nanoparticles using cannabinoids made from hemp, and processes for making the same.

The present invention provides formulations and methods for the treatment of Cannabis toxicity. The formulations can include THCV.

Tailored chromatographic media and methods for using the tailored chromatographic media to purify mixtures extracted from cannabis to obtain a cannabinoid having greater than about 90% purity. In an embodiment, the tailored chromatographic media may comprise a porous resin and/or porous carbon and have a surface area of greater than about 900 m2/g, wherein the tailored chromatographic media may further comprise micropores, mesopores, macropores, wherein the tailored chromatographic media may further comprise at least two distributions of macroporous pore sizes, wherein the at least two distributions of macroporous pore sizes may comprise a first population having a macroporous pore size denoted x and a second population having a macroporous pore size denoted y, wherein a ratio of x/y may be about 1:1, and wherein the tailored chromatographic media may further comprise an anionic polysaccharide and a functional moiety.